Pfizer is a general drug manufacturer company located in New York, United States, which is part of the Healthcare sector, and is traded under the ticker PFE on the NYSE exchange.
Pfizer stock last closed at $22.14, up 0.45% from the previous day, and has decreased 12.9% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.13 percentage points. Pfizer stock is currently +5.86% from its 52-week low of $20.92, and -29.8% from its 52-week high of $31.54.
As of Apr 17, 2025, there are 5.67B shares of PFE outstanding. The market cap of PFE is $125.47B. In the last 24 hours, 54.07M PFE shares were traded.
You will need an online brokerage account to access the NYSE market and buy PFE stock.
We believe that eToro is the best brokerage. eToro gives you:
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've picked your brokerage, you'll need to fill out some personal info so you are able to invest in PFE today.
Now that you have filled out your info on one of the most highly reviewed stock trading apps, you can securely and quickly fund your account:
Watch the walkthrough below for more details transferring funds into your new investment account.
After you have figured out the best place to buy Pfizer stock, it's very important to research their stock prior to investing, so you truly understand the risk as well as the upside.
WallStreetZen was created to help everyday investors do more accurate fundamental analysis.
You can view all of the due diligence checks on PFE's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge PFE's intrinsic value.
Using relative valuations metrics:
You can do more valuation research on PFE's stock here.
Out of 10 Equities analysts who give ratings on PFE, the consensus analyst rating on PFE is a Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
Srikripa Devarakonda, a bottom 9% analyst from Truist Securities maintains PFE with a strong buy rating and lowers their PFE price target from $36.00 to $32.00, on Dec 18, 2024.
Truist Securities's Srikripa Devarakonda lowered their price target on Pfizer (NYSE: PFE) by 11.1% from $36 to $32 on 2024/12/18. The analyst maintained their Strong Buy rating on the stock.
In a preview note, Devarakonda said they cut their price target on Pfizer because Truist Securities reduced its FY 2025 EPS estimate by $0.09 to $2.97 because of competitive pressures and the impact of the Inflation Reduction Act across multiple the company's portfolio, including Vyndaqel, Xeljanz, Eliquis, and its vaccine portfolio.
On the bright side, however, the analyst told readers that their firm believes that Pfizer's "continued launch execution and growing oncology presence" will ultimately "right the ship and return to the company to growth."
Tim Anderson, a top 32% analyst from Bank of America reinstates PFE with a hold rating and announces their PFE price target of $29.00, on Dec 10, 2024.
Alexandria Hammond, a bottom 22% analyst from Wolfe Research initiates coverage on PFE with a sell rating and announces their PFE price target of $25.00, on Nov 15, 2024.
Terence Flynn, a top 8% analyst from Morgan Stanley maintains PFE with a hold rating and raises their PFE price target from $30.00 to $31.00, on Oct 30, 2024.
Louise Chen, a bottom 4% analyst from Cantor Fitzgerald reiterates PFE with a strong buy rating and maintains their PFE price target from $45.00 to $45.00, on Oct 25, 2024.
You can dig deeper into what analysts are saying on the Pfizer stock forecast page.
Last year, PFE earnings were $8.03B. Over the past 5 year, PFE's earnings have grown by -13.19% per year. This was slower than the Drug Manufacturers - General industry average of 0.91%.
Last year, PFE revenue was $63.63B. During the last 5 year, PFE's revenue has gone up by 9.24% per year. This was faster than the Drug Manufacturers - General industry average of 9.2%.
You can research PFE's earnings and revenue performance here.
In the past 12 months, executives and large shareholders at PFE have bought more shares than they have sold.
Jennifer B. Damico, SVP Controller of PFE, was the latest PFE insider to sell. They sold $64,825.00 worth of PFE shares on Mar 4, 2025.
Get more info about who owns PFE stock here.
No, Pfizer doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
There are two primary order types:
Click the Open button and your broker will place your order.
If you require more help investing in stocks on eToro, click the how to video below:
Now that you own some PFE shares, you'll want to keep up with your new investment.
Add PFE to a watchlist to get the latest updates about your PFE stock.
To reiterate, here are the 6 steps to buy Pfizer stock:
If you need a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to keep track of your investment in Pfizer, click below.